Dr. de Jongh is CEO and Co-founder of AdaptVac since 2017, which has Virus-Like Particle (VLP) vaccine development projects against COVID-19 (out-licensed to Bavarian Nordic), Placental Malaria, Nipah and Filo viruses, as well as a vaccine against Her2+ breast cancer out-licensed to ExpreS2ion Biotechnologies. He further has >14 years C-level experience including as CSO and Co-founder of NASDAQ First North listed ExpreS2ion Biotechnologies. During this time he was involved in a range of research projects with partners, specifically in screening a large number of possible vaccine candidates and in developing a placental malaria vaccine production process in collaboration with the Center for Medical Parasitology in Copenhagen University. Furthermore, Dr. de Jongh managed the upstream process development and CMC transfer activities for a second blood stage malaria vaccine in collaboration with The Jenner Institute, Oxford University. The placental malaria project completed PhIa trials in Germany, and PhIb trial in Benin. The Jenner Institute has successfully developed the Rh5 malaria blood stage vaccine to a successful PhII study in Tanzania (2024), with further studies planned.KEY STRENGTHS• Scientific strategy• Insect cell line development for clinical use• Process development• CMC project transfer• Regulatory meetings• B2B relationship management• Project/Program management• Establishment of strategic collaborations • Grant funding application and management• Commercialization of high-tech products